MaxCyte Balance Sheet Health

Financial Health criteria checks 6/6

MaxCyte has a total shareholder equity of $221.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $251.5M and $30.2M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$157.33m
EquityUS$221.26m
Total liabilitiesUS$30.24m
Total assetsUS$251.50m

Recent financial health updates

Recent updates

MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 09
MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

May 30
Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

May 10
Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Mar 14
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Mar 07
Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%

Oct 07
Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Aug 12
Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

May 15
MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

May 14
Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Apr 27
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Nov 20
Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Mar 02
Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Nov 17
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn

Jul 25
We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn

MaxCyte (LON:MXCT) Shareholders Have Enjoyed A Whopping 545% Share Price Gain

Feb 22
MaxCyte (LON:MXCT) Shareholders Have Enjoyed A Whopping 545% Share Price Gain

Financial Position Analysis

Short Term Liabilities: MXCT's short term assets ($175.6M) exceed its short term liabilities ($12.3M).

Long Term Liabilities: MXCT's short term assets ($175.6M) exceed its long term liabilities ($18.0M).


Debt to Equity History and Analysis

Debt Level: MXCT is debt free.

Reducing Debt: MXCT had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MXCT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MXCT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 22.5% each year


Discover healthy companies